Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE
NCT07503925Phase 4Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Maximum Plasma Nicotine Concentration at 2 weeks. Started Jun 2026; status: recruiting.
Beyond the preview
Go deeper on NCT07503925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503925.